Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy

Nature Materials

Volumn 11, Issue 10, 2012, Pages 895-905

  Park, Jason ^a   Wrzesinski, Stephen H ^b,c   Stern, Eric ^a   Look, Michael ^a   Criscione, Jason ^a   Ragheb, Ragy ^a   Jay, Steven M ^a   Demento, Stacey L ^a   Agawu, Atu ^a   Licona Limon, Paula ^b   Ferrandino, Anthony F ^b   Gonzalez, David ^b   Habermann, Ann ^b   Flavell, Richard A ^b,c   Fahmy, Tarek M ^a,c  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIODEGRADABLE POLYMERS; ENZYME INHIBITION; GELS; IMMUNE SYSTEM; NANOTECHNOLOGY; T-CELLS;

ADAPTIVE IMMUNE RESPONSE; CELL INFILTRATION; METASTATIC MELANOMA; MICROENVIRONMENTS; MOLECULAR INHIBITORS; NATURAL KILLER CELLS; TRANSFORMING GROWTH FACTOR BETA; WATER SOLUBLE PROTEIN;

TUMORS;

ANTINEOPLASTIC AGENT; CYCLODEXTRIN; INTERLEUKIN 2; LIPOSOME; NANOMATERIAL; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG FORMULATION; EXPERIMENTAL NEOPLASM; GEL; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; METHODOLOGY; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; ANIMALS; ANTINEOPLASTIC AGENTS; CYCLODEXTRINS; DRUG COMPOUNDING; GELS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; LIPOSOMES; MICE; MICE, INBRED STRAINS; NANOSTRUCTURES; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84866743713     PISSN: 14761122     EISSN: 14764660     Source Type: Journal    
DOI: 10.1038/nmat3355     Document Type: Article

References (48)

1. Tawbi, H. A. & Kirkwood, J. M. Management of metastatic melanoma. Semin. Oncol. 34, 532-545 (2007).
2. Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
3. Acquavella, N. et al. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J. Immunother. 31, 569-576 (2008).
4. Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Limon, P. The polarization of immune cells in the tumour environment by TGFβ. Nature Rev. Immunol. 10, 554-567 (2010).
5. Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Med. 7, 1118-1122 (2001).
6. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176, 1582-1587 (2006).
7. Wrzesinski, S. H., Wan, Y. Y. &Flavell, R. A. Transforming growth factor-β and the immune response: Implications for anticancer therapy. Clin. Cancer Res. 13, 5262-5270 (2007).
8. + T regulatory cells:Roleoftumor-derived TGF-β. J. Immunol. 178, 2883-2892 (2007).
9. Fan, T. M., Kranz, D. M. & Roy, E. J. Enhancing antitumor immunity: combining IL-12 with TGFβ1 antagonism. J. Immunother. 30, 479-489 (2007).
10. Yingling, J. M., Blanchard, K. L.&Sawyer, J. S.DevelopmentofTGF- β signaling inhibitors for cancer therapy. Nature Rev. Drug. Disc. 3, 1011-1022 (2004).
11. Neville, M. E., Boni, L., Pflug, L., Popescu, M. C. & Robb, R. J. Biopharmaceutics of liposomal IL-2. Oncol. Cytok. 12, 1691-1701 (2000).
12. Feng, X-H. & Derynck, R. Specificity and versatility in TGF-β signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659-693 (2005).
13. Kano, M. R. et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl Acad. Sci. USA 104, 3460-3465 (2007).
14. Laouar, Y., Sutterwala, F. S., Gorelik, L. & Flavell, R. A. Transforming growth factor-beta control T helper type 1 cell development through regulation of natural killer interferon-gamma. Nature Immunol. 6, 600-607 (2005).
15. Terabe, M. & Berzofsky, J. A. The role of NKT cells in tumor immunity. Adv. Cancer Res. 101, 277-348 (2008).
16. Gillies, S. D. et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin. Cancer Res. 17, 3673-3685 (2011).
17. Teppler, H.et al. Prolonged immunostimulatory effectoflow-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection. J. Exp. Med. 177, 483-492 (1993).
18. Letourneau, S. et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc. Natl Acad. Sci. USA 107, 2171-2176 (2010).
19. Kaufman, H. L., Flanagan, K., Lee, C. S., Perretta, D. J. & Horig, H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 20, 1862-1869 (2002).
20. Kanaoka, E. et al. A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture). J. Control. Rel. 82, 183-187 (2002).
21. Neville, M. E., Robb, R. J. & Popescu, M. C. In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2. Cytokine 16, 239-250 (2001).
22. Town, T. et al. Blocking TGF-β-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nature Med. 14, 681-687 (2008).
23. Byfield, S. D., Major, C., Laping, N. J. & Roberts, A. B. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol. Pharm. 65, 744-752 (2004).
24. Allen, T. M. & Martin, F. J. Advantages of liposomal delivery systems for anthracyclines. Semin. Oncol. 31, 5-15 (2004).
25. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nature Rev. Drug. Disc. 4, 145-160 (2005).
26. Mundargi, R. C., Babu, V. R., Rangaswamy, V., Patel, P. & Aminabhavi, T. M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J. Control Release 125, 193-209 (2008).
27. Thevenot, J., Troutier, A-L., David, L., Delair, T. & Ladavire, C. Steric stabilization of lipid/polymer particle assemblies by poly(ethylene glycol)-lipids. Biomacromole 8, 3651-3660 (2007).
28. Moghimi, S. M. & Szebeni, J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42, 463-478 (2003).
29. Moghimi, S. M., Hunter, A. C. & Murray, J. C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev. 53, 283-318 (2001).
30. Kazakov, S.&Levon, K.Liposome-nanogel structures for future pharmaceutical applications. Curr. Pharm Des. 12, 4713-4728 (2006).
31. Meng, H. et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4, 4539-4550 (2010).
32. Meng, H. et al. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. J. Am. Chem. Soc. 132, 12690-12697 (2010).
33. Liong, M. et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2, 889-896 (2008).
34. Ashley, C. E. et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nature Mater. 10, 389-397 (2011).
35. Sawhney, A. S., Pathak, C. P. & Hubbell, J. A. Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly(α-hydroxy acid) diacrylate macromers. Macromole 26, 581-587 (1993).
36. Van Thienen, T. G., Raemdonck, K., Demeester, J. & De Smedt, S. C. Protein release from biodegradable dextran nanogels. Langmuir 23, 9794-9801 (2007).
37. Loftsson, T. & Duchene, D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 329, 1-11 (2007).
38. Stella, J. & He, Q. Cyclodextrins. Toxicol. Pathol. 36, 30-42 (2008).
39. Cote-Sierra, J. et al. Interleukin 2 plays a central role in Th2 differentiation. Proc. Natl Acad. Sci. USA 101, 3880-3885 (2004).
40. Al-Soufi, W. et al. Fluorescence correlation spectroscopy, a tool to investigate supramolecular dynamics: inclusion complexes of pyronines with cyclodextrin. J. Am. Chem. Soc. 127, 8775-8784 (2005).
41. Wu, S. et al. Photoreversible fluorescence modulation of a rhodamine dye by supramolecular complexation with photosensitive cyclodextrin. Angew. Chem. Int. Ed. 46, 7015-7018 (2007).
42. Farokhzad, O. C. et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103, 6315-6320 (2006).
43. Wischke, C. & Schwendeman, S. P. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int. J. Pharm. 364, 298-327 (2008).
44. Van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
45. + T cells. Immunity 31, 131-144 (2009).
46. Hori, Y., Stern, P. J., Hynes, R. O. & Irvine, D. J. Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy. Biomaterials 30, 6757-6767 (2009).
47. Moon, J. J. et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nature Mater. 10, 243-251 (2011).
48. Peer, D., Park, E. J., Morishita, Y., Carman, C. V. & Shimaoka, M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627-630 (2008).